ProMIS Neurosciences Inc.
For the period ended Mar 25, 2026. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 25, 2026 · Filed Mar 25, 2026
PMN$4.16+14.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Key Pipeline Programs
Key Pipeline Programs
| ● | Development of subcutaneous formulation for PMN310 |
| o | We have accelerated the development of a subcutaneous formulation of PMN310 and established a dedicated development plan, reflecting our conviction in the potential of this approach to improve patient experience and strengthen the asset's competitive profile. |
| ● | Amyotrophic Lateral Sclerosis Disease Program (PMN267) |
| o | PMN267 is the lead preclinical candidate antibody directed against toxic misfolded TDP-43 as a potential therapeutic target for ALS and other TDP-43 proteinopathies (e.g. frontotemporal dementia). It has demonstrated strict selectivity for pathogenic TDP-43 and protective activity in antibody and intrabody formats. PMN267 has been humanized in a human IgG1 framework for IND-enabling studies. |
| ● | Parkinson’s Disease (PD), Dementia with Lewy Bodies and Multiple System Atrophy (MSA) Disease Program (PMN442) |
| o | ProMIS selected PMN442 as the lead candidate antibody for PD and other synucleinopathies based on its selective binding and protective activity against pathogenic forms of alpha-synuclein. It has been humanized in a human IgG1 framework for IND-enabling studies. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.